Global Leukotriene Inhibitors Market – Industry Trends and Forecast to 2029

Global Leukotriene Inhibitors Market, By Drugs (Montelukast, Zafirlukast, Zileuton, Others), Indication (Asthma, COPD, Allergic Rhinitis, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029

Leukotriene Inhibitors Market Analysis and Size

The global leukotriene inhibitors market is expected to witness significant growth during the forecast period. The growth of leukotriene inhibitors market enhanced by the growing cases of chronic obstructive lung disease and asthma worldwide and environmental change. These inhibitors lead to tightening of airway muscles and excess mucus and fluid production. In addition, advances in the treatment options and the presence of well-established healthcare facilities are some of the impacting factors for the growth of leukotriene inhibitors market. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global leukotriene inhibitors market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Leukotriene inhibitors, also known as antileukotrienes or leukotriene modifiers, is a medication widely used to treat respiratory diseases associated with an allergic response. It works by preventing leukotrienes, inflammatory mediators from binding to their receptors.  

Report Scope and Market Segmentation

Global Leukotriene Inhibitors Market Dynamics

Drivers

• Increase in Allergy Diseases

Prevalence of allergic diseases witnessed was approximately 30%, which is about 1 billion globally. As per the reports of the European Academy of Allergy and Clinical Immunology (EAACI), allergy was reported to be the most common chronic disease in Europe in 2016. Back in 2012, around 17.6 million adults and 6.6 million children were witnessed to suffer from allergic rhinitis. This boosts the market growth.

Opportunities

• Increasing Drug Launches and Approvals

There are several drugs that has been launched and approved for the benefit of the market. The U.S. FDA has approved Montelukast for prophylaxis and chronic treatment of asthma in adults, and for children above one year. This drug is used in prevention of bronchoconstriction induced due to exercise. Likewise, other drugs such as Zafirlukast, Zileuton, and Zileuton E.R. are also used in chronic treatment of asthma in adults, and children between the age group of 5-12 years. This is another factor expected to drive growth of the leukotriene inhibitors market.  

• Increasing Demand for Retail Pharmacies

The rise in the number of leukotriene inhibitors delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

• Lack of Insurance Coverage

There are several side-effects of leukotriene inhibitors that restrain the market growth. Side effects such as headache, gastrointestinal disorders, fatigue, upper respiratory tract infection, pharyngitis, cutaneous rash and reversible alterations in levels of serum transaminase hamper the growth of the market.

• High Cost

The huge expenditure associated with these agents surely hamper the market growth.

This global leukotriene inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global leukotriene inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Leukotriene Inhibitors Market            

Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials.

In the post-pandemic era, the biotechnology and pharmaceutical industries are expected to witness a huge future growth due to the demand for vaccine and treatment drugs for COVID-19. Thus, this will leave a significant impact on the global leukotriene inhibitors market.

Global Leukotriene Inhibitors Market Scope

The global leukotriene inhibitors market is segmented on the basis of drug, indication, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

• Montelukast
• Zafirlukast
• Zileuton
• Others

Indication

• Asthma
• COPD
• Allergic Rhinitis
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Leukotriene Inhibitors Market Regional Analysis/Insights

The global leukotriene inhibitors market is analysed and market size insights and trends are provided by drug, indication, distribution channel and end-user as referenced above.

The major countries covered in the global leukotriene inhibitors market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global leukotriene inhibitors market throughout the forecasted period due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.

North America dominates the market due to the global leaders in research and development activities and vulnerable asthma population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Leukotriene Inhibitors Market Share Analysis

The global leukotriene inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global leukotriene inhibitors market

Key players operating in the global leukotriene inhibitors market include:

• Mallinckrodt plc  (U.K.)
• Sun Pharmaceutical Industries Ltd. (India)
• Novartis AG (Switzerland)
• Endo Pharmaceuticals plc (Ireland)
• Zydus Cadila (India)
• Mylan N.V. (U.S.)
• Mayne Pharma Group Limited (Australia)
• Teva Pharmaceutical Industries Ltd (Israel)
• Amneal Pharmaceutical Inc (U.S.)
• Avet Pharmaceuticals Inc. (U.S.)
• Aurobindo Pharma (India)
• GSK plc (UK)
• Almirall, S.A (Spain)
• Merck & Co., Inc. (Germany)
• Bausch Health (Canada)
• Sandoz International GmbH (Germany)
• Pfizer Inc. (U.S.)
• AstraZeneca (U.K.)
• Sanofi (France)
• Bayer AG (Germany)
• McKesson Corporation (U.S.)